Department of Clinical and Experimental Medicine, University of Padua, Italy.
J Hepatol. 2010 Jan;52(1):45-53. doi: 10.1016/j.jhep.2009.10.014. Epub 2009 Oct 23.
BACKGROUND & AIMS: It is established that cirrhotic patients who respond to beta-blockers by lowering their hepatic venous pressure gradient (HVPG) to < or =12 mmHg or by > or =20% of the baseline values are protected from bleeding. However, it is not known whether the effect remains unchanged over the treatment period.
A group of 24 patients with cirrhosis and oesophageal varices, treated with beta-blockers+/-nitrates, good-responders on haemodynamic criteria, were followed for up to 76 months with sequential HVPG measurements. Another group of 16 patients was used for validation.
HVPG worsened in 10 of the 24 patients during follow-up. Changes in HVPG correlated to concomitant changes in liver function parameters. Variceal bleeding occurred in four of the 10 patients whose HVPG had worsened (bleed; 3-21 months after the measured increase in HVPG) and in none of those with stable HVPG (p=0.02). Patients with increased HVPG also had shorter survival (p=0.05). Worsening of HVPG was an independent predictor of death, additive to Child-Pugh or MELD scores, in a time-dependent Cox's regression analysis. This relationship was confirmed in the validation group.
Worsening HVPG during follow-up in patients who had initially been good-responders to medical treatment is related to worsening in hepatic function. The maintenance of a good haemodynamic response to medical treatment of portal hypertension is an excellent predictor of outcome in these patients.
已经证实,通过降低肝静脉压力梯度(HVPG)至<或=12mmHg 或基线值的>或=20%而对β受体阻滞剂有反应的肝硬化患者可以防止出血。然而,尚不清楚这种效果在治疗期间是否保持不变。
一组 24 例患有肝硬化和食管静脉曲张的患者,接受β受体阻滞剂+/-硝酸盐治疗,根据血流动力学标准为良好反应者,在最多 76 个月的时间内进行了连续的 HVPG 测量。另一组 16 例患者用于验证。
在随访期间,24 例患者中有 10 例 HVPG恶化。HVPG 的变化与肝功能参数的同时变化相关。在 HVPG 增加的 10 例患者中有 4 例(在 HVPG 测量增加后的 3-21 个月)发生了静脉曲张出血,而在 HVPG 稳定的患者中无出血(p=0.02)。HVPG 增加的患者生存时间也更短(p=0.05)。在时间依赖性 Cox 回归分析中,HVPG 恶化是死亡的独立预测因素,可附加于 Child-Pugh 或 MELD 评分。在验证组中也证实了这种关系。
在最初对药物治疗有良好反应的患者中,随访期间 HVPG 的恶化与肝功能恶化有关。维持对门静脉高压症的良好药物治疗反应是这些患者预后的极好预测因素。